09/11/2018 18:49:52

Adamas to Present at Three November Investor Conferences

Related content
10 Jan - 
Adamas Announces New Employment Inducement Grant
06 Jan - 
Adamas Provides Preliminary Fourth Quarter and Full-Yea..
18 Dec - 
Adamas Announces Issuance of New U.S. Patent Covering G..

EMERYVILLE, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at the following three investor conferences:

  • Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 at 2:50 p.m. MST (4:50 p.m. EST)
  • Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018 at 11:00 a.m. EST
  • Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018 at 8:00 a.m. EST

The presentations will be webcast live from the investor relations section of the Adamas website at https://ir.adamaspharma.com/events-presentations. Archived versions of the webcasts will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.

Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only medicine approved by the U.S. Food and Drug Administration for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.

Contacts:

Investors:

Ashleigh Barreto

Director, Corporate Communications and Investor Relations

Adamas Pharmaceuticals, Inc.

510-450-3567

ir@adamaspharma.com

Media:

Terri Clevenger

Continuum Health Communications

203-227-0209

tclevenger@continuumhealthcom.com

Adamas Pharmaceuticals Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Kitov Closes $6 Million Registered Direct Offering
2
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Danske Bank A/S – DNKEY
3
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Natural Health Trends Corporation – NHTC
4
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AxoGen, Inc. - AXGN
5
Tesla Announces Date for Fourth Quarter and Full Year 2018 Financial Results and Webcast

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 January 2019 11:25:54
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190108.3 - EUROWEB3 - 2019-01-19 12:25:54 - 2019-01-19 11:25:54 - 1000 - Website: OKAY